Free Trial Information
BioCentury | Aug 17, 2018
Clinical News

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

...gained the PDS technology from ForSight Vision4 Inc. when the pharma acquired the biotech in 2017 (see "ForSight Vision4...
Read More
BioCentury | Jan 27, 2017
Company News

ForSight Vision4, Roche deal

...Roche acquired ForSight Vision4 for an undisclosed upfront payment and undisclosed development and sales milestones. Roche gained...
...as Lucentis . Roche did not respond to inquiries, and ForSight Vision4 could not be reached. ForSight Vision4 Inc....
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Drug delivery, Ophthalmic Jaime De Leon Lucentis ranibizumab RG3645 Roche Vascular endothelial growth factor A (VEGF-A) ForSight Vision4 Inc....
Read More
BioCentury | Oct 10, 2016
Finance

M&Allergan

Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is still nearly full. Allergan's bank account swelled to nearly $37 billion...
Read More
BioCentury | Aug 22, 2016
Company News

Allergan, ForSight Vision5 deal

Allergan acquired ForSight Vision5 for $95 million in cash and an undisclosed milestone tied to the launch of ForSight’s Helios ocular insert . The insert, which delivers bimatoprost, a prostaglandin analog over a period of multiple...
Read More
BioCentury | Jun 22, 2016
Company News

Management tracks

Endocyte Inc. (NASDAQ:ECYT) said Ron Ellis resigned as president and CEO. The cancer company promoted CFO and COO Mike Sherman to succeed Ellis. Sherman will remain CFO. Bristol-Myers Squibb Co. (NYSE:BMY) promoted Murdo Gordon to...
Read More
BioCentury | Apr 21, 2014
Financial News

ForSight Vision5 completes venture financing

ForSight Vision5 Inc. , Menlo Park, Calif. Business: Ophthalmic Date completed: 4/16/14 Type: Venture financing Raised: $15 million Investors: H.I.G. BioVentures; Morgenthaler Ventures; Versant Ventures ; Technology Partners; Delphi Ventures WIR Staff Ophthalmic...
Read More
BioCentury | Apr 16, 2014
Financial News

ForSight Vision5 raises $15 million in series C

ForSight Vision5 Inc. (Menlo Park, Calif.) raised $15 million in a series C round led by new investor H.I.G. BioVentures. Existing investors Morgenthaler Ventures; Versant Ventures; Technology Partners; and Delphi Ventures also participated. H.I.G.'s Aaron...
Read More
BioCentury | Jan 16, 2012
Company News

ForSight Vision4 Inc., Roche deal

...apply the device to other select targets to treat ophthalmic disorders. Details were not disclosed. ForSight Vision4 Inc....
Read More
BioCentury | Jan 14, 2012
Company News

Genentech pays first milestone in ForSight deal

...Genentech Inc. said it will make an undisclosed milestone payment to ForSight Vision4 Inc. (Menlo Park, Calif.) under...
Read More
Items per page:
1 - 9 of 9
BioCentury | Aug 17, 2018
Clinical News

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

...gained the PDS technology from ForSight Vision4 Inc. when the pharma acquired the biotech in 2017 (see "ForSight Vision4...
Read More
BioCentury | Jan 27, 2017
Company News

ForSight Vision4, Roche deal

...Roche acquired ForSight Vision4 for an undisclosed upfront payment and undisclosed development and sales milestones. Roche gained...
...as Lucentis . Roche did not respond to inquiries, and ForSight Vision4 could not be reached. ForSight Vision4 Inc....
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Drug delivery, Ophthalmic Jaime De Leon Lucentis ranibizumab RG3645 Roche Vascular endothelial growth factor A (VEGF-A) ForSight Vision4 Inc....
Read More
BioCentury | Oct 10, 2016
Finance

M&Allergan

Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is still nearly full. Allergan's bank account swelled to nearly $37 billion...
Read More
BioCentury | Aug 22, 2016
Company News

Allergan, ForSight Vision5 deal

Allergan acquired ForSight Vision5 for $95 million in cash and an undisclosed milestone tied to the launch of ForSight’s Helios ocular insert . The insert, which delivers bimatoprost, a prostaglandin analog over a period of multiple...
Read More
BioCentury | Jun 22, 2016
Company News

Management tracks

Endocyte Inc. (NASDAQ:ECYT) said Ron Ellis resigned as president and CEO. The cancer company promoted CFO and COO Mike Sherman to succeed Ellis. Sherman will remain CFO. Bristol-Myers Squibb Co. (NYSE:BMY) promoted Murdo Gordon to...
Read More
BioCentury | Apr 21, 2014
Financial News

ForSight Vision5 completes venture financing

ForSight Vision5 Inc. , Menlo Park, Calif. Business: Ophthalmic Date completed: 4/16/14 Type: Venture financing Raised: $15 million Investors: H.I.G. BioVentures; Morgenthaler Ventures; Versant Ventures ; Technology Partners; Delphi Ventures WIR Staff Ophthalmic...
Read More
BioCentury | Apr 16, 2014
Financial News

ForSight Vision5 raises $15 million in series C

ForSight Vision5 Inc. (Menlo Park, Calif.) raised $15 million in a series C round led by new investor H.I.G. BioVentures. Existing investors Morgenthaler Ventures; Versant Ventures; Technology Partners; and Delphi Ventures also participated. H.I.G.'s Aaron...
Read More
BioCentury | Jan 16, 2012
Company News

ForSight Vision4 Inc., Roche deal

...apply the device to other select targets to treat ophthalmic disorders. Details were not disclosed. ForSight Vision4 Inc....
Read More
BioCentury | Jan 14, 2012
Company News

Genentech pays first milestone in ForSight deal

...Genentech Inc. said it will make an undisclosed milestone payment to ForSight Vision4 Inc. (Menlo Park, Calif.) under...
Read More
Items per page:
1 - 9 of 9